Forge Biologics Expands Gene Therapy Manufacturing Role With Progeria Partnership

A LinkedIn post from Forge Biologics highlights a new manufacturing partnership with The Progeria Research Foundation focused on advancing a gene therapy for the fatal genetic disease Progeria. The post indicates that Forge will provide process development and manufacturing expertise in collaboration with researchers including Drs. Leslie Gordon, David R. Liu, and Francis Collins.

The partnership suggests growing demand for Forge’s adeno-associated virus gene therapy development and manufacturing capabilities in highly specialized rare-disease programs. For investors, this type of collaboration may signal strengthening positioning in the gene therapy contract development and manufacturing market, potentially supporting longer-term revenue visibility and scientific credibility in complex, high-impact indications.